The LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) was the study that transformed how researchers understand GLP-1 receptor agonism. Before LEADER, GLP-1R agonists were studied primarily as glucose-lowering agents with a side effect of modest weight reduction. LEADER established that sustained GLP-1R activation produces clinically meaningful cardiovascular protection — a finding that reshaped the entire class and set the template for SUSTAIN-6 (semaglutide), SURPASS-CVOT (tirzepatide), and SELECT (semaglutide obesity) that followed.
Trial Design and Population
LEADER enrolled 9,340 patients with type 2 diabetes and established cardiovascular disease or multiple CV risk factors. Patients were randomised to liraglutide 1.8mg SC daily or placebo, added to standard of care (background glucose-lowering therapy permitted). Median follow-up was 3.8 years — the longest of any GLP-1R agonist CVOT at the time.
| Design element | Detail |
|---|---|
| Population | 9,340 T2DM patients — established CVD or high CV risk (age ≥50 + ≥1 CV risk factor, or ≥60 + ≥1 risk factor) |
| Intervention | Liraglutide 1.8mg SC once daily vs matching placebo |
| Background therapy | Standard care permitted — metformin, SGLT2i, sulphonylurea, insulin |
| Primary endpoint | 3-point MACE: CV death, non-fatal MI, non-fatal stroke — time to first event |
| Follow-up | Median 3.8 years (range 0–5 years) |
| Design | Double-blind, placebo-controlled, event-driven RCT — superiority design |
| Sponsor | Novo Nordisk — EMA/FDA post-marketing cardiovascular safety requirement |
Primary and Secondary Results
| Endpoint | Liraglutide | Placebo | HR (95% CI) | p-value |
|---|---|---|---|---|
| 3-point MACE (primary) | 13.0% | 14.9% | 0.87 (0.78–0.97) | p=0.01 (superiority) |
| CV death | 4.7% | 6.0% | 0.78 (0.66–0.93) | p=0.007 |
| Non-fatal MI | 6.0% | 6.8% | 0.88 (0.75–1.03) | p=0.11 |
| Non-fatal stroke | 3.4% | 3.8% | 0.89 (0.72–1.11) | p=0.30 |
| Hospitalisation for HF | 4.7% | 5.3% | 0.87 (0.73–1.05) | p=0.14 |
| All-cause mortality | 8.2% | 9.6% | 0.85 (0.74–0.97) | p=0.02 |
| HbA1c change (52 wk) | −1.1% | −0.4% | — | — |
| Body weight change (52 wk) | −2.3 kg | −0.2 kg | — | — |
What drove the mortality reduction?
The 13% MACE reduction was driven primarily by the CV death component (22% RRR, HR 0.78) — not by MI or stroke, which showed non-significant trends. This suggests the mechanism is not purely plaque stabilisation or anti-thrombotic, but includes direct cardiac and/or vascular effects. The dissociation between CV death reduction and non-fatal MI/stroke reduction has driven subsequent research into the direct cardiac GLP-1R mechanism.
Mechanistic Hypotheses — What Caused the Benefit?
The LEADER trial was not designed to identify mechanism — it was an outcomes trial. But the pattern of results has generated several mechanistic hypotheses that subsequent basic science has explored:
Hypothesis 1 — Direct cardiac GLP-1R activation
GLP-1 receptors are expressed on ventricular cardiomyocytes and sinoatrial node cells. Direct GLP-1R activation → cAMP/PKA → reduced ischaemia-reperfusion injury, improved cardiac function under stress. Mouse IR studies show GLP-1R agonists reduce infarct size independently of metabolic effects. The predominant CV death (vs MI/stroke) reduction in LEADER is consistent with a direct cardiac mechanism rather than anti-atherosclerotic.
Hypothesis 2 — Anti-inflammatory and endothelial effects
GLP-1R is expressed on endothelial cells and macrophages. Liraglutide reduces NF-kB activation, ICAM-1 expression, and macrophage foam cell formation in vitro. In ApoE-/- mice, GLP-1R agonists reduce aortic plaque area and inflammatory infiltrate. Circulating CRP and IL-6 are mildly reduced by liraglutide in clinical studies — consistent with systemic anti-inflammatory contribution.
Hypothesis 3 — Metabolic and haemodynamic improvements
Liraglutide reduces blood pressure (−2-3 mmHg systolic in LEADER), weight (−2.3 kg), and improves postprandial glucose excursions. These metabolic improvements reduce cumulative CV risk over 3.8 years. However, the magnitude of metabolic benefit is modest — unlikely to fully explain a 13% MACE reduction. The direct cardiac/vascular mechanisms likely contribute independently.
Current consensus: multi-factorial
The LEADER benefit likely reflects a combination: direct cardiac GLP-1R cardioprotection + anti-inflammatory/endothelial effects + modest metabolic improvements. The relative contribution of each mechanism remains an active research area — and is why studies using direct GLP-1R agonist injection (bypassing metabolic confounders) alongside cardiac GLP-1R knockout models are needed to dissect the mechanism.
Research Implications — What LEADER Changed
LEADER fundamentally changed the research agenda for GLP-1R agonists in three ways:
1. Established cardiovascular outcomes as the primary efficacy benchmark. Before LEADER, GLP-1R agonist research was glucose-centric. After LEADER, CVOT data became the key differentiator — driving SUSTAIN-6 (semaglutide 2.4% NNT 46 for MACE), SURPASS-CVOT (tirzepatide ongoing), and SELECT (semaglutide in obesity without T2DM — 20% MACE reduction). Every subsequent GLP-1R agonist now requires CVOT data for regulatory approval.
2. Identified CV death (not MI/stroke) as the primary mechanism target. The asymmetry between CV death reduction (significant) and MI/stroke (non-significant trends) in LEADER drove research into direct cardiac GLP-1R mechanisms, cardiac IR protection, and the role of cardiac vs vascular GLP-1R expression. This mechanistic question remains open.
3. Made liraglutide the reference compound. All subsequent GLP-1R agonists are now compared against liraglutide’s LEADER benchmark. Semaglutide’s SUSTAIN-6 MACE HR (0.74) vs liraglutide’s LEADER HR (0.87) drives the clinical perception of semaglutide as superior — though the trials differ in duration and population. For preclinical researchers, liraglutide remains the reference GLP-1R agonist for CV protection studies.
Frequently Asked Questions
What was the LEADER trial?
LEADER was a 9,340-patient double-blind RCT in T2DM patients with high CV risk, comparing liraglutide 1.8mg daily vs placebo over a median 3.8 years. It showed 13% RRR for 3-point MACE (HR 0.87, p=0.01) and 22% RRR for CV death — establishing liraglutide as the first GLP-1R agonist with demonstrated cardiovascular protection.
Why was the CV death reduction larger than MI/stroke reduction in LEADER?
CV death was reduced 22% (HR 0.78, significant) while non-fatal MI (HR 0.88) and stroke (HR 0.89) showed non-significant trends. This pattern suggests the mechanism involves direct cardiac GLP-1R protection rather than purely anti-atherosclerotic effects. Direct cardiac GLP-1R activation reduces ischaemia-reperfusion injury and improves cardiac function under stress — effects that would reduce sudden cardiac death more than MI or embolic stroke.
How does LEADER compare to other GLP-1R CVOT trials?
LEADER (liraglutide): HR 0.87, 3.8yr, T2DM+CVD. SUSTAIN-6 (semaglutide): HR 0.74, 2.1yr, T2DM+CVD — lower HR but shorter trial. SELECT (semaglutide, obesity/no T2DM): HR 0.80, 3.3yr — extended benefit to non-diabetic obese population. SURPASS-CVOT (tirzepatide): ongoing as of 2025. Direct comparison is difficult due to different populations, durations, and event rates.
Is liraglutide still used in research after semaglutide?
Yes — liraglutide remains the reference GLP-1R agonist for several reasons: LEADER provides the largest and longest CVOT dataset for any GLP-1R agonist; its 13-hour half-life allows once-daily dosing with faster washout than semaglutide; and its FDA/EMA approval for both T2DM (Victoza) and obesity (Saxenda) provides regulatory context. For preclinical research requiring daily dosing or faster pharmacokinetics, liraglutide remains preferable to semaglutide.